-
Ejection Fraction Pros and Cons: JACC State-of-the-Art ReviewTH Marwick -
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced TrialSD Anker, J Butler, EMPEROR-Reduced Trial Committees and Investigators et al.
-
Vericiguat in Patients with Heart Failure and Reduced Ejection FractionPW Armstrong, B Pieske, the VICTORIA Study Group
-
2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure)B Bozkurt, RE Hershberger, J Butler et al.
-
Prdm16 Deficiency Leads to Age-Dependent Cardiac Hypertrophy, Adverse Remodeling, Mitochondrial Dysfunction, and Heart FailureDM Cibi, KW Bi-Lin, MK Singh et al.
-
Left Ventricular Assist Devices: Synergistic Model Between Technology and MedicineJJ Han, MA Acker, P Atluri et al.
-
SGLT2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF TrialsF Zannad, JP Ferreira, SJ Pocock et al.
-
Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine - The ROPA-DOP TrialK Sharma, Stuart D. Russell and on behalf of the Osler Medical Housestaff.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
